Literature DB >> 9733887

An adenovirus type 5 mutant with the preterminal protein gene deleted efficiently provides helper functions for the production of recombinant adeno-associated virus.

I H Maxwell1, F Maxwell, J Schaack.   

Abstract

Production of recombinant adeno-associated virus (rAAV) requires helper functions that have routinely been provided by infection of the producer cells with adenovirus. Complete removal and/or inactivation of progeny adenovirus, present in such rAAV preparations, presents significant difficulty. Here, we report that an adenovirus type 5 (Ad5) mutant with the preterminal protein (pTP) gene deleted can provide helper function for the growth of rAAV. At high multiplicity, Ad5dl308DeltapTP was as efficient as the phenotypically wild-type Ad5dl309 in permitting growth of rAAV. Use of Ad5dl308DeltapTP, which is incapable of replication in the absence of complementation for pTP, as a helper avoids the need to remove contaminating adenovirus infectious activity by heat inactivation or by purification. Comparison of the transducing ability of rAAV generated with either Ad5dl308DeltapTP or Ad5dl309 as a helper demonstrated that the heat inactivation protocol generally used does not remove all of the helper Ad5dl309 function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733887      PMCID: PMC110217     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  19 in total

1.  Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap.

Authors:  J E Conway; S Zolotukhin; N Muzyczka; G S Hayward; B J Byrne
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells.

Authors:  K M Johnston; D Jacoby; P A Pechan; C Fraefel; P Borghesani; D Schuback; R J Dunn; F I Smith; X O Breakefield
Journal:  Hum Gene Ther       Date:  1997-02-10       Impact factor: 5.695

3.  Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products.

Authors:  K A Vincent; S T Piraino; S C Wadsworth
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

5.  293 cell lines that inducibly express high levels of adenovirus type 5 precursor terminal protein.

Authors:  S J Langer; J Schaack
Journal:  Virology       Date:  1996-07-01       Impact factor: 3.616

6.  A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome.

Authors:  K J Fisher; W M Kelley; J F Burda; J M Wilson
Journal:  Hum Gene Ther       Date:  1996-11-10       Impact factor: 5.695

7.  Improved production of recombinant AAV by transient transfection of NB324K cells using electroporation.

Authors:  F Maxwell; G S Harrison; I H Maxwell
Journal:  J Virol Methods       Date:  1997-01       Impact factor: 2.014

8.  Characterization of a replication-incompetent adenovirus type 5 mutant deleted for the preterminal protein gene.

Authors:  J Schaack; X Guo; S J Langer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

9.  Isolation of deletion and substitution mutants of adenovirus type 5.

Authors:  N Jones; T Shenk
Journal:  Cell       Date:  1978-01       Impact factor: 41.582

10.  Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors.

Authors:  F K Ferrari; T Samulski; T Shenk; R J Samulski
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

View more
  2 in total

1.  Transduction of ovarian cancer cells: a recombinant adeno-associated viral vector compared to an adenoviral vector.

Authors:  J Vermeij; Z Zeinoun; B Neyns; E Teugels; C Bourgain; J De Grève
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

Review 2.  Pharmacology of Recombinant Adeno-associated Virus Production.

Authors:  Magalie Penaud-Budloo; Achille François; Nathalie Clément; Eduard Ayuso
Journal:  Mol Ther Methods Clin Dev       Date:  2018-01-08       Impact factor: 6.698

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.